Business
Notice of Results and Investor Presentation
ProBiotix Health plc has announced that its audited results for the year ended 31 December 2025 will be released on Monday, 30 March 2026. The company's Chief Executive and Chief Finance Officer will present these results via Investor Meet Company on the same day at 10:00 BST, offering an opportunity for existing and potential shareholders to ask questions. Disclaimer*
About this update from Probiotix Health Plc
16 March 2026 ProBiotix Health plc ("ProBiotix" or the "Company" or, together with its subsidiary, the "Group") Notice of Results and Investor Presentation ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, today confirms that it will release its audited results for the year ended 31 December 2025 on Monday, 30 March 2026. Investor Presentation Steen Andersen, Chief Executive, and Mark Collingbourne, Chief Finance Officer, will provide a live presentation relating to the Full Year Results, via Investor Meet Company on 30 March 2026 at 10:00 BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 29 March 2026, 09:00 BST, or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet ProBiotix Health via: https://www.investormeetcompany.com/probiotix-health-plc/register-investor Investors who already follow ProBiotix Health on the Investor Meet Company platform will automatically be invited. For further information, please contact: ProBiotix Health plc https://probiotixhealth-ir.com/ [email protected] Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations AlbR Capital Limited Aquis Corporate Adviser and Broker Tel: 020 7469 0930 This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement. Notes to Editors: ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals. The Company has a singular approach: discovering groundbreaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.
View stock analysis, news, and events for Probiotix Health Plc